NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
February 20 2024 - 3:01PM
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company
focused on discovering and developing transformative therapeutics
for patients, today announced that David J. Woodhouse, Ph.D., Chief
Executive Officer, will participate in a corporate panel discussion
on novel oncology targets at the Cowen 44th Annual Health Care
Conference on Tuesday, March 5th, at 9:10 am ET.
A live webcast of the presentation will be available under the
Investors and Media sections of NGM Bio’s website at
https://ir.ngmbio.com/events-presentations. A replay of the
presentation will be archived on NGM Bio’s site for 30 days
following the event.
About NGM Bio
NGM Bio is focused on discovering and developing novel,
life-changing medicines for people whose health and lives have been
disrupted by disease. NGM Bio’s biology-centric drug discovery
approach aims to seamlessly integrate interrogation of complex
disease-associated biology and protein engineering expertise to
unlock proprietary insights that are leveraged to generate
promising product candidates and enable their rapid advancement
into proof-of-concept studies. All therapeutic candidates in the
NGM Bio pipeline have been generated by its in-house discovery
engine, always led by biology and motivated by unmet patient need.
Visit us at www.ngmbio.com for more information.
Investor Contact: |
Media
Contact: |
ir@ngmbio.com |
media@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Nov 2024 to Dec 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Dec 2023 to Dec 2024